Details
Therapeutic categorythe type of treatment or therapy being studied. A therapy could range from a medication addressing a particular characteristic of CF to a device or activity e.g. exercise
Mucociliary Clearance
Phasethe different stages involved in the development of a new medication. Phase I focuses on initial safety in people. Phase 2 evaluates safety, correct dose and early signs of whether the medication works. Phase 3 is the stage before medication licensing and looks at safety and medication effectiveness. Phase 4 evaluates longer term use of a medication after it has been licensed for use
Phase II
Full title
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis (HOPE-1 Study: Hydration for Optimal Pulmonary Effectiveness)
Evaluation of potential mucus clearing treatment for all patients with CF regardless of mutation
Trial Reference Number
99066
Trial type
Medication
Interventionthe name of the treatment or therapy being researched
ENaC inhibitor (mucociliary clearance)
Recruitment targetthe number of participants who need to be recruited for the trial in the UK
80
Last edited date
02 October 2017
CF sponsor
Spyryx Biosciences, Inc.
CF sponsor type
Commercial
Add to watchlist